Review of glyburide after one year on the market (Q39849368)

15 September 2017

1 reference

title

Review of glyburide after one year on the market (English)

1 reference

15 September 2017

J M Feldman

1

1 reference

PubMed ID

3931457

15 September 2017

language of work or name

English

0 references

publication date

1 September 1985

1 reference

American Journal of Medicine

15 September 2017

1 reference

15 September 2017

79

1 reference

15 September 2017

102-108

1 reference

15 September 2017

3B

1 reference

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Comparison of chlorpropamide and glibenclamide treatment of maturity-onset diabetes: control assessed by fasting plasma glucose concentrations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Once-daily use of glyburide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

TWO YEARS' EXPERIENCE WITH ACETOHEXAMIDE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Chlorpropamide-induced hyponatremia: incidence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Increase of Plasma Acetaldehyde: An Objective Indicator of the Chlorpropamide Alcohol Flush

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Drug Interactions with Oral Sulphonylurea Hypoglycaemic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Displacement of tolbutamide, glibencalmide and chlorpropamide from serum albumin by anionic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Drug-induced hypoglycemia. A review based on 473 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Glibenclamide-associated hypoglycaemia: a report on 57 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Radioimmunoassay for Glyburide in Human Serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Behaviour of glibenclamide on repeated administration to diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Improved effect of glibenclamide on administration before breakfast.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

[Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

[Combination therapy with insulin and sulfonylurea in secondary failure of sulfonylurea therapy]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Effect of insulin therapy on insulin resistance in type II diabetic subjects. Evidence for heterogeneity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Which patients might benefit from combining a sulfonylurea with insulin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

The metabolic response to glycemic control by the artificial pancreas in diabetic man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2885%2980015-2

10.1016/S0002-9343(85)80015-2

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

3931457